Gamida Cell Ltd. (NASDAQ:GMDA) shares traded 6.06% higher at $1.40 on Wall Street last session.
In accordance with the data, 4 analysts cover Gamida Cell Ltd. (NASDAQ:GMDA). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $11.00 and a low of $5.00, we find $6.00. Given the previous closing price of $1.32, this indicates a potential upside of 354.55 percent. GMDA stock price is now -25.50% away from the 50-day moving average and -11.56% away from the 200-day moving average. The market capitalization of the company currently stands at $151.77M.
It has been rated a hold by 0 analysts and a buy by 4. Brokers who have rated the stock have averaged $7.00 as their price target over the next twelve months.
With the price target of $11, Alliance Global Partners recently initiated with Buy rating for Gamida Cell Ltd. (NASDAQ: GMDA).
In other news, Blum Robert I, Director bought 50,000 shares of the company’s stock on Sep 30. The stock was bought for $77,500 at an average price of $1.55. Upon completion of the transaction, the Director now directly owns 52,000 shares in the company, valued at $72800.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 30, President and CEO Jenkins Abigail L. bought 16,129 shares of the business’s stock. A total of $25,000 was incurred on buying the stock at an average price of $1.55. This leaves the insider owning 266,129 shares of the company worth $0.37 million. A total of 0.70% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in GMDA stock. A new stake in Gamida Cell Ltd. shares was purchased by DENALI ADVISORS LLC during the first quarter worth $83,000. VIRTU FINANCIAL LLC invested $46,000 in shares of GMDA during the first quarter. In the first quarter, D. E. SHAW & CO., INC. acquired a new stake in Gamida Cell Ltd. valued at approximately $31,000. TWO SIGMA INVESTMENTS, LP acquired a new stake in GMDA for approximately $29,000. RAYMOND JAMES FINANCIAL SERVICES ADVISORS, INC. purchased a new stake in GMDA valued at around $28,000 in the second quarter. In total, there are 66 active investors with 33.30% ownership of the company’s stock.
Gamida Cell Ltd. (NASDAQ: GMDA) opened at $1.3000 on Wednesday. During the past 12 months, Gamida Cell Ltd. has had a low of $0.56 and a high of $3.66. The fifty day moving average price for GMDA is $1.8690 and a two-hundred day moving average price translates $1.5812 for the stock.
The latest earnings results from Gamida Cell Ltd. (NASDAQ: GMDA) was released for Mar, 2023. For the current quarter, analysts expect GMDA to generate $160k in revenue.
Gamida Cell Ltd.(GMDA) Company Profile
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company’s lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.
